THE RELATIONSHIP BETWEEN OCULAR ITCH, OCULAR PAIN, AND DRY EYE SYMPTOMS (An American Ophthalmological Society Thesis)

By Anat Galor MD MSPH, Leslie Small OD, William Feuer MS, Roy C. Levitt MD, Konstantinos D. Sarantopoulos MD PhD, and Gil Yosipovitch MD

ABSTRACT

Purpose: To evaluate associations between sensations of ocular itch and dry eye (DE) symptoms, including ocular pain, and DE signs.

Methods: A cross-sectional study of 324 patients seen in the Miami Veterans Affairs eye clinic was performed. The evaluation consisted of questionnaires regarding ocular itch, DE symptoms, descriptors of neuropathic-like ocular pain (NOP), and evoked pain sensitivity testing on the forehead and forearm, followed by a comprehensive ocular surface examination including corneal mechanical sensitivity testing. Analyses were performed to examine for differences between those with and without subjective complaints of ocular itch.

Results: The mean age was 62 years with 92% being male. Symptoms of DE and NOP were more frequent in patients with moderate-severe ocular itch compared to those with no or mild ocular itch symptoms. With the exception of ocular surface inflammation (abnormal matrix metalloproteinase 9 testing) which was less common in those with moderate-severe ocular itch symptoms, DE signs were not related to ocular itch. Individuals with moderate-severe ocular itch also demonstrated greater sensitivity to evoked pain on the forehead and had higher non-ocular pain, depression, and post-traumatic stress disorders scores, compared to those with no or mild itch symptoms.

Conclusions: Subjects with moderate-severe ocular itch symptoms have more severe symptoms of DE, NOP, non-ocular pain and demonstrate abnormal somatosensory testing in the form of increased sensitivity to evoked pain at a site remote from the eye, consistent with generalized hypersensitivity.


INTRODUCTION

Itch is a common complaint in the general population, affecting between 8 and 38% worldwide. It can appear as an idiopathic complaint or in the setting of known conditions such as eczema or psoriasis. Itch has also been reported a common complaint in primary Sjogrens syndrome (pSS), a disease whose hallmark is aqueous tear deficient dry eye (DE). In one study, 10 subjects with pSS and chronic itch were compared to 9 subjects with pSS and no chronic itch. Those with itch reported that it was chronic (mean duration ~6 years) and severe (mean 7.7 on a visual analogue scale). Interestingly, xerosis (i.e. dryness) was more common in those with itch compared to those without (9, 90% versus 4, 44%).

In the eye, the classic teaching attributes the presence of itch to allergy. Yet, a recent paper reported that ocular itch associated not only with allergic conjunctivitis (OR=5.0; 95% CI 3.0 to 8.3) but also with DE (OR=2.6; 95% CI 1.7 to 4.1). DE, however, is not one disease and includes both DE symptoms (sensations of dryness, pain, and visual disturbances) and signs (decreased tear production, increased evaporation, ocular surface inflammation), which are often disparate. It is not known which components of DE (specific symptoms, signs, or both) associate with ocular itch.

To fill this gap, in this study, we evaluate which aspects of DE most closely align with ocular itch, including non-ocular metrics associated with DE in prior studies. Based on shared neurobiological mechanisms, we hypothesize that ocular itch more closely relates to DE symptoms, especially ocular pain, as compared to DE signs. Data to support this hypothesis comes from the shared role of thermosensitive transient receptor potential (TRP) channel proteins in transmitting multiple sensations (itch, pain, and dryness). Furthermore, inflammation, a component of DE and skin conditions associated with itch, can alter TRP channel function with increased excitability of peripheral nociceptors. Prolonged peripheral traffic can alter central neurons, with resulting pain amplification expressed as hyperalgesia and allodynia. Finally, DE symptoms and itch are co-morbid with disorders of central processing, namely depression, anxiety, and insomnia.

METHODS

STUDY POPULATION

Patients with otherwise healthy eyelid and corneal anatomy were prospectively enrolled from the Miami Veterans Affairs eye clinic from October 2013 to August 2016. To study patients with “idiopathic” DE symptoms, we excluded patients with conditions known to underlie DE symptoms including infection, contact lens use, history of refractive, glaucoma, or retina surgery, cataract surgery within
the preceding 6 months, use of ocular medications other than artificial tears, human immunodeficiency virus, sarcoidosis, graft-versus-host disease, or collagen vascular diseases. Miami Veterans Affairs Institutional Review Board approved the prospective evaluation of patients. The study was conducted in accordance with the principles of the Declaration of Helsinki and complied with the requirements of the United States Health Insurance Portability and Accountability Act. All subjects signed an informed consent form.

DATA COLLECTED

For each individual, demographic information, past ocular and medical history and medication information were collected.

DRY EYE SYMPTOMS

Subjects completed the dry eye questionnaire 5 (DEQ5)17 and the Ocular Surface Disease Index (OSDI).18 The DEQ5 is a validated, 5-item questionnaire that combines patient responses regarding discomfort (frequency and intensity), dryness (frequency and intensity), and watery eyes (frequency) during the past month. DEQ5 scores range from 0 to 22, with higher scores corresponding to greater severity of symptoms. The OSDI is also a validated DE questionnaire that grades symptoms (sensitivity to light, grittiness, soreness, blurred or poor vision), triggers (wind, low humidity, air conditioning), and degree of disability associated with symptoms (limitations in reading, driving, working on the computer, watching television) over a 1 week recall. It is scored on a 0 to 100 scale, with higher scores indicating greater symptoms and disability.

OCULAR ITCH

Individuals were asked to rate the severity of their ocular itch as none, mild, moderate, or severe. This schema was based on the short-form McGill Pain questionnaire which utilizes a similar scale to assess for the presence of sensory and affective pain descriptors.19

OCULAR PAIN

Subjects rated the intensity of their average eye pain over a 1-week period using a numerical rating scale (NRS; 0 for “no pain sensation”, 10 for “the most intense eye pain imaginable”). A modified Neuropathic Pain Symptom Inventory (NPSI) was administered to evaluate neuropathic ocular pain-like symptoms (NPSI-Eye, range 0-100). The modified version replaced the original items regarding allodynia and hyperalgesia in the setting of light touch, pressure, or contact with something cold on the skin with items specific to ocular hyperalgesia and allodynia (namely, eye pain caused or increased by wind, light, and/or heat or cold). The NPSI has been validated as a self-report instrument for assessing neuropathic pain,20 and has been found to correlate with mechanical and/or thermal allodynia and hyperalgesia assessed using Quantitative Sensory Testing (QST).21

OCULAR SURFACE EVALUATION

The ocular surface evaluation, in the order performed, included (1) tear osmolarity (TearLAB, San Diego, CA, once in each eye); (2) ocular surface inflammation (Inflammadry, Quidel, San Diego, CA presence of matrix metalloprotease 9, once in each eye); (3) tear breakup time (5 µl fluorescein placed, 3 averaged measurements in each eye); (4) corneal epithelial cell disruption via corneal staining (National Eye Institute scale)22, 5 areas of cornea assessed with a score of 0-3 in each, range 0-15; (6) tear production via Schirmer’s strips (mm wetting measured at 5 minutes after placement of proparacaine); and (7) meibomian gland assessment. Eyelid vascularia was graded 0-3 (0 = none; 1 = mild engorgement; 2 = moderate engorgement; 3 = severe engorgement, based on photographs) and meibum quality was graded 0-4 (0 = clear; 1 = cloudy; 2 = granular; 3 = toothpaste; 4 = no meibum extracted).23

DE DISCORDANCE SCORE

Discordance scores were calculated similarly to Vehof et al.24 Values representing DE symptoms (OSDI) and signs (osmolarity, TBUT, corneal staining, Schirmer, eyelid vascularia, meibum quality, more severe value of two eyes) were transformed to a common unit severity score between 0 (representing the most normal value) and 1 (representing the most abnormal value) using linear interpolation. A composite signs severity score was then calculated by averaging the transformed scores of the six DE signs. The DE discordance score was defined as the difference between the transformed score on the OSDI and the transformed score on the composite signs severity score. DE discordance scores could potentially range from -1 (minimal symptoms, maximal signs) to 1 (maximal symptoms, minimal signs). A positive discordance score indicates more symptoms than signs.

CORNEAL SENSITIVITY

Mechanical detection and pain thresholds of the right central cornea were assessed with a modified Belmonte non-contact aesthesiometer, developed based on the original instrument.25 The tip (0.5 mm diameter) was placed perpendicular to and 4 mm from the surface of the cornea of the right eye. Stimulation consisted of pulses of air at room temperature.26 The method of limits, using ascending series only, was used to measure detection and pain thresholds with highest value for both being 400 mL/min.27

CUTANEOUS SENSITIVITY

Testing was performed over the right forehead, at a site approximately two finger widths above the superior orbital fissure and in line with the pupil, and over the ventral right forearm, on the skin overlying the midpoint between the wrist and cubital fossa. A TSA II (Thermal Sensory Analyzer; Medoc Ltd., Israel) machine was used to assess cold and hot pain thresholds to stimuli delivered via a square thermode (9cm² surface area). The starting temperature was set at 32 °C and cooled (or heated) using the software accompanying the machine. Per the ascending method of limits, the probe temperature gradually decreased (for cold pain thresholds at a rate of 2°C/sec) or increased (for hot pain thresholds, at a rate of 2°C/sec) until the subject pressed a button (placed in the left hand)
to indicate the first moment that he/she perceived pain, or the cut-off temperature was reached (0ºC for cold trials, 50ºC for heat trials). Three trials for cold pain and three trials for hot pain were performed at each test site, with an inter-trial-interval of 45 seconds. Results of the three trials for each modality were averaged and are reported as the absolute change from baseline temperature (32ºC). Thus, higher values for both heat and cold indicate that a greater change in temperature was needed for the subject to report pain. In addition, ratings of pain intensity at threshold for cold pain and hot pain were recorded using a 0 to 100 numerical rating scale, where 0=“no pain” and 100=“the most intense pain imaginable.”

**NON-OCULAR PAIN SEVERITY AND MENTAL HEALTH**

A NRS for concurrent non-ocular pain was used (“How would you describe the overall intensity of your pain, on average during the last week?” and “How would you describe the overall intensity of your pain, at its worst during the last week?” scale 0-10). Symptoms of PTSD were assessed via the PTSD Checklist – Military Version (score 17-85)\(^{28}\) and symptoms of depression via the Patient Health Questionnaire 9 (score 0-27).\(^{29}\)

**STATISTICAL ANALYSIS**

Individuals were grouped by the presence of itch rated on a 0 to 3 scale, with “0” indicating no itch, “1” indicating mild itch, “2”indicating moderate itch and a “3” indicating severe itch. Statistical analyses were performed using SPSS 22.0 (SPSS Inc, Chicago, IL) statistical package. Student t-test, Mann Whitney U, linear-by-linear association, and Fisher exact tests were used to compare variables of interest between the groups. The sample size of 124 moderate-severe ocular itch patients, 130 patients with mild itch, and 70 without itch provides 80% power to detect ANOVA effect sizes of 0.230, which corresponds to differences seen in QST testing, and more than 95% power to detect effect sizes of 0.3, which corresponds to differences seen in patient reported symptoms.

**RESULTS**

**DEMOGRAPHICS AND CO-MORBIDITIES BY ITCH SUBGROUPS**

324 subjects participated in the study (mean age 62 years, 92% men). Of those, 254 individuals reported a sensation of ocular itch: 130 rated the sensation as “mild” in intensity, 79 “moderate”, and 45 “severe”. Full demographic characteristics of the sample, grouped by sensation of itch, are presented in Table 1. Demographics and co-morbidities were similar between groups. A higher proportion of patients with moderate-severe ocular itch were on anxiolytics, antidepressant, and analgesics than their counterparts with no or mild ocular itch.

| TABLE 1. DEMOGRAPHICS AND CO-MORBIDITIES OF STUDY POPULATION BY RESPONSE TO SENSATION OF ITCH |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Demographics                                                  | NO OCULAR ITCH (n=70)                                         | MILD OCULAR ITCH (n=130)                                      | MODERATE-SEVERE OCULAR ITCH (n=124)                           | P-VALUE                                                      |
| Age, years mean (SD)                                          | 62 (9)                                                       | 62 (10)                                                      | 62 (11)                                                      | 0.96                                                         |
| Gender, male, n (%)                                           | 63 (90%)                                                     | 118 (91%)                                                    | 116 (94%)                                                    | 0.35                                                         |
| Race, white, n (%)                                            | 39 (56%)                                                     | 62 (48%)                                                     | 62 (50%)                                                     | 0.52                                                         |
| Ethnicity, Hispanic, n (%)                                    | 18 (26%)                                                     | 34 (26%)                                                     | 42 (34%)                                                     | 0.18                                                         |
| Co-morbidities, n (%)                                         |                                                              |                                                              |                                                              |                                                              |
| Hypertension                                                  | 54 (77%)                                                     | 97 (75%)                                                     | 84 (68%)                                                     | 0.13                                                         |
| Hypercholesteremia                                            | 40 (57%)                                                     | 84 (65%)                                                     | 71 (57%)                                                     | 0.82                                                         |
| Diabetes mellitus                                             | 19 (27%)                                                     | 42 (32%)                                                     | 32 (26%)                                                     | 0.69                                                         |
| Sleep apnea                                                   | 13 (19%)                                                     | 27 (21%)                                                     | 30 (24%)                                                     | 0.34                                                         |
| BPH                                                           | 10 (14%)                                                     | 20 (15%)                                                     | 26 (21%)                                                     | 0.20                                                         |
| Chronic pain (≥3 months) co-morbidities                       |                                                              |                                                              |                                                              |                                                              |
| Number chronic pain conditions, mean (SD)                     | 2.3 (1.5)                                                    | 2.4 (1.6)                                                    | 3.0 (1.5)                                                    | 0.001                                                        |
| Number chronic pain locations, mean (SD)                     | 3.7 (2.9)                                                    | 3.7 (2.9)                                                    | 4.6 (3.2)                                                    | 0.03                                                         |
| Headache, n (%)                                               | 22 (31%)                                                     | 40 (31%)                                                     | 50 (40%)                                                     | 0.23                                                         |
| Back Pain, n (%)                                              | 50 (71%)                                                     | 83 (64%)                                                     | 93 (75%)                                                     | 0.15                                                         |
| Muscle Pain, n (%)                                            | 23 (33%)                                                     | 48 (37%)                                                     | 60 (48%)                                                     | 0.06                                                         |
| Tendonitis, n (%)                                             | 11 (17%)                                                     | 30 (25%)                                                     | 31 (27%)                                                     | 0.33                                                         |
| Sciatica, n (%)                                               | 20 (29%)                                                     | 28 (22%)                                                     | 28 (23%)                                                     | 0.51                                                         |
| Arthritis, n (%)                                              | 30 (43%)                                                     | 56 (43%)                                                     | 64 (52%)                                                     | 0.19                                                         |

Trans Am Ophthalmol Soc / 115 / 2017
TABLE 1. CONTINUED

<table>
<thead>
<tr>
<th></th>
<th>NO OCULAR ITCH (n=70)</th>
<th>MILD OCULAR ITCH (n=130)</th>
<th>MODERATE-SEVERE OCULAR ITCH (n=124)</th>
<th>P-VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-Surgical Pain, n (%)</td>
<td>15 (21%)</td>
<td>28 (22%)</td>
<td>27 (22%)</td>
<td>0.99</td>
</tr>
<tr>
<td>Diabetic Neuropathy, n (%)</td>
<td>12 (17%)</td>
<td>25 (19%)</td>
<td>20 (16%)</td>
<td>0.81</td>
</tr>
<tr>
<td>Trigeminal Neuralgia, n (%)</td>
<td>2 (3%)</td>
<td>6 (5%)</td>
<td>6 (5%)</td>
<td>0.79</td>
</tr>
<tr>
<td>Medications, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiolytic</td>
<td>26 (37%)</td>
<td>51 (39%)</td>
<td>65 (52%)</td>
<td>0.02</td>
</tr>
<tr>
<td>Antidepressant</td>
<td>30 (43%)</td>
<td>49 (38%)</td>
<td>67 (54%)</td>
<td>0.06</td>
</tr>
<tr>
<td>Anti-histamine</td>
<td>15 (21%)</td>
<td>23 (18%)</td>
<td>29 (23%)</td>
<td>0.61</td>
</tr>
<tr>
<td>Analgesics</td>
<td>34 (49%)</td>
<td>70 (54%)</td>
<td>87 (71%)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

SD=standard deviation; n=number in each group; BPH=benign prostatic hypertrophy

DE SYMPTOMS AND OCULAR SURFACE SIGNS BY ITCH

All DE symptoms, including neuropathic-like ocular pain symptoms, were higher in patients with moderate-severe ocular itch compared to their counterparts with no or mild ocular itch (Table 2). In fact, the frequency of severe DE symptoms increased with increased degree of ocular itch (Figure 1, p<0.0005). However, DE signs were not related to itch, with the exception of ocular inflammation (via matrix metalloproteinase (MMP) 9 detection) which was less common in those with moderate-severe ocular itch, although the difference did not reach statistical significance. When evaluating DE discordance scores, those with moderate-severe ocular itch had higher discordance scores (mean 0.35 standard deviation (SD) 0.28) compared to individuals without (0.11 SD 0.26) or with mild (0.17 SD 0.24) ocular itch (Figure 2). Clinically, this indicates that the group of individuals with moderate-severe ocular itch had a higher degree of DE symptoms compared to signs than individuals without or with mild itch.

### TABLE 2. DRY EYE SYMPTOMS AND OCULAR SURFACE EXAMINATION IN STUDY POPULATION BY ITCH SUBGROUPS

<table>
<thead>
<tr>
<th></th>
<th>NO ITCH (n=70)</th>
<th>MILD ITCH (n=130)</th>
<th>MODERATE-SEVERE ITCH (n=124)</th>
<th>P-VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dry eye symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEQ5 (range 0-22)</td>
<td>7.9 (6.1)</td>
<td>10.7 (4.4)</td>
<td>14.1 (3.4)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>OSDI (range 0-100)</td>
<td>25.1 (25.4)</td>
<td>29.5 (21.5)</td>
<td>47.4 (24.2)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>Ocular pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain intensity averaged past week (range 0-10)</td>
<td>2.1 (2.7)</td>
<td>2.7 (2.3)</td>
<td>4.7 (2.4)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>Hot-burning pain (range 0-10)</td>
<td>1.4 (2.6)</td>
<td>2.3 (2.6)</td>
<td>4.3 (3.2)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>Sensitivity to wind (range 0-10)</td>
<td>1.6 (2.8)</td>
<td>1.7 (2.5)</td>
<td>4.5 (3.4)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>Sensitivity to light (range 0-10)</td>
<td>2.5 (3.7)</td>
<td>2.3 (2.7)</td>
<td>4.5 (3.3)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>NPSI-Eye (range 0-100)</td>
<td>12.7 (17.5)</td>
<td>15.3 (16.2)</td>
<td>33.8 (23.7)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>Ocular surface findings</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tear osmolarity*, mOsm/L</td>
<td>308 (19)</td>
<td>305 (14)</td>
<td>305 (16)</td>
<td>0.39</td>
</tr>
<tr>
<td>Tear film breakup time*, seconds</td>
<td>10.0 (5.2)</td>
<td>9.9 (4.0)</td>
<td>9.6 (4.9)</td>
<td>0.79</td>
</tr>
<tr>
<td>Corneal staining* (range 0-15)</td>
<td>2.4 (3.0)</td>
<td>1.8 (2.3)</td>
<td>1.8 (2.2)</td>
<td>0.23</td>
</tr>
<tr>
<td>Schirmer’s test*, mm of moisture</td>
<td>11.9 (7.4)</td>
<td>14.4 (7.6)</td>
<td>14.2 (8.2)</td>
<td>0.54</td>
</tr>
<tr>
<td>Eyelid vascularity* (range 0-3)</td>
<td>0.52 (0.70)</td>
<td>0.60 (0.76)</td>
<td>0.65 (0.79)</td>
<td>0.18</td>
</tr>
<tr>
<td>Meibum quality* (range 0-4)</td>
<td>1.7 (1.3)</td>
<td>1.9 (1.2)</td>
<td>2.0 (1.2)</td>
<td>0.14</td>
</tr>
<tr>
<td>Ocular surface inflammation in either eye, n (%)†</td>
<td>23 (43%)</td>
<td>39 (42%)</td>
<td>29 (30%)</td>
<td>0.08</td>
</tr>
<tr>
<td>Corneal evoked mechanical sensitivity, mL/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corneal detection threshold**</td>
<td>96 (45)</td>
<td>93 (44)</td>
<td>87 (44)</td>
<td>0.38</td>
</tr>
<tr>
<td>Corneal pain threshold**</td>
<td>238 (109)</td>
<td>218 (99)</td>
<td>219 (112)</td>
<td>0.46</td>
</tr>
</tbody>
</table>

DEQ5=Dry Eye Questionnaire; OSDI=Ocular Surface Disease Index questionnaire; NPSI-Eye= neuropathic pain symptom inventory modified for the eye; *represents value from more severely affected eye; †= ocular surface inflammation is expressed as a percentage and not a mean; **tested in the right eye only.
SYSTEMIC PROFILES BY ITCH SUBGROUPS

Patient reported non-ocular pain and mental health indices were higher in those with moderate-severe ocular itch compared to those with no or mild itch. (Table 3) Individuals with moderate-severe ocular itch had lower hot pain thresholds at a site remote from the eye (forearm) indicating increased cutaneous sensitivity.

<table>
<thead>
<tr>
<th>Patient reported symptoms</th>
<th>NO ITCH (n=70)</th>
<th>MILD ITCH (n=130)</th>
<th>MODERATE-SEVERE ITCH (n=124)</th>
<th>P-VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-ocular pain intensity, averaged over past week (range 0-10)</td>
<td>3.7 (3.0)</td>
<td>4.5 (2.9)</td>
<td>5.8 (2.7)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>PTSD checklist Military Version (range 17-85)</td>
<td>35 (20)</td>
<td>35 (17)</td>
<td>48 (20)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>Depression via PHQ9 (range 0-27)</td>
<td>7.1 (8.1)</td>
<td>7.2 (7.0)</td>
<td>12.5 (8.2)</td>
<td>&lt;0.0005</td>
</tr>
</tbody>
</table>

**Cutaneous sensitivity over forehead**

| Cold pain threshold, change from 32°C | 18.5°C (10.8) | 19.1°C (9.4) | 16.9°C (10.7) | 0.48 |
| Pain intensity rating at cold pain threshold | 37.5 (26.4) | 39.7 (25.0) | 41.5 (25.1) | 0.75 |
| Hot pain threshold, change from 32°C | 12.0°C (4.1) | 11.9°C (6.9) | 11.7°C (4.6) | 0.95 |
| Pain intensity rating at hot pain threshold | 46.8 (27.6) | 46.8 (26.2) | 47.0 (25.8) | 0.99 |

**Cutaneous sensitivity over forearm**

| Cold pain threshold, change from 32°C | 19.2°C (10.2) | 20.2°C (9.5) | 16.7°C (10.4) | 0.14 |

FIGURE 1

Bar graph demonstrating that subjects with increasing ocular itch severity also had increasing dry eye symptoms severity.

FIGURE 2

Box plot demonstrating that patients with moderate-severe ocular itch had a greater discordance between symptoms and sign (higher symptoms, lower signs) compared to those without or with mild ocular itch.
TABLE 3. CONTINUED

<table>
<thead>
<tr>
<th></th>
<th>NO ITCH (n=70)</th>
<th>MILD ITCH (n=130)</th>
<th>MODERATE-SEVERE ITCH (n=124)</th>
<th>P-VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain intensity rating at cold pain threshold</td>
<td>32.7 (28.9)</td>
<td>38.2 (26.4)</td>
<td>38.6 (25.3)</td>
<td>0.54</td>
</tr>
<tr>
<td>Hot pain threshold, change from 32°C</td>
<td>12.4°C (4.7)</td>
<td>12.7°C (4.2)</td>
<td>10.5°C (4.8)</td>
<td>0.02</td>
</tr>
<tr>
<td>Pain intensity rating at hot pain threshold</td>
<td>46.3 (27.9)</td>
<td>46.6 (25.5)</td>
<td>46.7 (27.1)</td>
<td>0.99</td>
</tr>
</tbody>
</table>

SD=standard deviation; PTSD= post-traumatic stress disease; PHQ=Patient Health questionnaire; *information available in 162 patients as only a sub-set of population underwent quantitative sensory testing

DISCUSSION

The current study evaluated the relationship between various DE symptoms, signs, and somatosensory findings by severity of ocular itch. We found that patients with moderate-severe ocular itch had more severe DE symptoms including those consistent with NOP with no differences in ocular surface measures. Additionally, moderate to severe ocular itch associated with increased cutaneous pain sensitivity, a higher discordance between symptoms and ocular surface signs, and higher non-ocular pain and mental health complaints. This suggests that various ocular sensations, which can include dryness, itch, and pain (e.g. burning, aching, and tenderness) have shared underlying mechanisms. Consequently, the remaining discussion will focus on potential commonalities (and unique differences) between these sensations and their translation to DE management.

THE ETIOLOGY OF ITCH, CHRONIC PAIN AND DE

Itch and pain are related but distinct sensations. In acute disease, mechanisms underlying itch and pain are often disparate, while in chronic disease, shared mechanisms underlie the pathophysiology. Similar considerations apply to sensations of dryness. Below we discuss how chronic sensations are driven by disorders of the nervous system prompted by immune dysfunction (Table 4).31

TABLE 4. SIMILARITIES BETWEEN CHRONIC ITCH AND PAIN AND ITS POTENTIAL IMPLICATIONS IN DRY EYE (DE).

<table>
<thead>
<tr>
<th>SIMILARITIES BETWEEN CHRONIC ITCH AND PAIN</th>
<th>ITCH SPECIFIC</th>
<th>RELEVANCE TO DE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Unpleasant, source of morbidity, affect quality of life</td>
<td>Itch evokes scratching while pain induces withdrawal</td>
</tr>
<tr>
<td>Co-morbidities</td>
<td>Depression and anxiety common co-morbidities</td>
<td>Depression and anxiety common co-morbidities</td>
</tr>
<tr>
<td>Inflammation</td>
<td>Inflammation induces and maintains sensitization</td>
<td>IL-31 more specific to itch</td>
</tr>
<tr>
<td>Other mediators</td>
<td>Nerve growth factor involved</td>
<td>Nerve growth factor increased in the tears of individuals with DE</td>
</tr>
<tr>
<td>Peripheral Transmission and Sensitization</td>
<td>Both involve increased responsiveness of peripheral nociceptive neurons, with changes in TRP function</td>
<td>G protein-coupled receptors (Mrgpr and PAR2) involved in non-histaminic mediated chronic itch.</td>
</tr>
<tr>
<td>Central Transmission and Sensitization</td>
<td>Both involve increased CNS excitatory and decreased inhibitory signal transmission</td>
<td>Gastrin-releasing peptide (GRP) receptor expressing neurons essential for itch transmission.</td>
</tr>
<tr>
<td>Higher order processing</td>
<td>Multiple areas of brain involved, both sensory and affective. Both sensations are not a direct measure of input</td>
<td>Precuneus involved.</td>
</tr>
</tbody>
</table>
**TABLE 4. CONTINUED**

| Supporting cells | Interaction between nerves with epithelial, immune and glial cells occurs in peripheral and central nervous system | Corneal epithelial cells interact and support corneal nerves in a manner similar to Schwann cells |
| Treatment | Both respond in some degree to neuropathic pain medication | Anti-neuropathic pain medication can be considered as an adjuvant to ocular surface optimization in those with a suspected neuropathic component to DE symptoms (whether sensations of itch, pain, or dryness) |

**PERIPHERAL INFLAMMATION**

Inflammation is an important component of chronic pain, itch, and DE.

**Peripheral inflammation and chronic pain.** Injury to epithelial cells leads to the release of various mediators such as adenosine 5'-triphosphate (ATP), histamine, serotonin, bradykinin, and prostaglandin (PG) E2 which stimulate peripheral nerves to release inflammatory mediators such as substance P and calcitonin gene-related peptide (CGRP).32 These mediators co-activate resident antigen presenting cells and recruit additional immune cells to the site of injury.33-35 Immune cells release additional soluble mediators such as tumor necrosis factor (TNF) α and interleukin (IL) 1β that promote sensitization of nociceptors via gene expression and modulation of ion channels.36 In addition, nerve growth factor is secreted by keratinocytes and can cause sprouting and reorganization of nerves.

**Peripheral inflammation and chronic itch.** Similar mechanisms have been found in itch. In the skin, mast cells and keratinocytes interact and sensitize peripheral neurons. Specifically T cells release specific cytokines, IL-2 and IL-31, which have been involved with itch.31

**Relevance to dry eye.** Ocular surface inflammation is an important component in DE. Many mediators implicated in non-ocular pain and itch, such as TNFα, IL1, IL6, PGE2, MMP-9, serotonin, and NGF are elevated in the tears of patients with DE. Cellular inflammation also plays a role in DE with T cells detected more frequently in the conjunctivae of DE patients.42 The enhanced soluble and cellular inflammatory milieu described on the ocular surface in DE likely promotes peripheral sensitization in a similar fashion to that seen elsewhere in the body (Figure 3). Interestingly, both DE and non-ocular pain have been found to have a hereditary component43, 44 with genetic polymorphisms in pro-inflammatory genes (e.g. IL1 and IL6R) associated with DE in a Korean population.45

**Neuropathic pain.** Both nociceptive and neuropathic mechanisms likely play a role in chronic itch and DE. Nociceptive pain (defined as pain that arises from actual or threatened damage to non-neural tissue and is due to the activation of nociceptors)46 is driven by chronic ocular surface abnormalities that are seen in many DE sub-types (pSS, graft versus host disease). With time, inflammation, trauma, and chronic activation of nociceptors can lead to permanent changes in nociceptor structure and function (i.e. sensitization) that can occur both peripherally and/or centrally, thus adding a neuropathic component to the pain (defined as a pain due to a lesion or disease of the somatosensory system46).

**Peripheral sensitization.** Immune cells are in close proximity to peripheral nerves and their interactions can lead to peripheral sensitization (defined as reduced threshold and increased responsiveness of peripheral nociceptor neurons in response to stimulation of their receptive fields46).

**Peripheral sensitization and chronic pain.** Inflammation sensitizes peripheral nerves by enhancing the function of ion channels, including TRP channels (TRPV1 senses heat, chemicals, and abnormal pH and TRPM8 senses cooling) and voltage-gated sodium (Nav1.7-1.9), calcium, and potassium channels through phosphorylation and translation of new channels.47 Electrophysiologically, sensitized nerves demonstrate enhanced transduction (generation of an action potential) and conduction (propagation of the action potential).48 Spontaneous peripheral nerve activity may develop in several locations including adjacent uninjured afferent fibers and damaged axonal endings. Neuroma formation is a common finding in patients with pain in the setting of traumatic peripheral nerve injuries.48 Sodium channel activity has been found to be altered in neuromas, leading to modified sodium currents and abnormal ectopic firings.49
 FIGURE 3

Diagram showing potential shared pathways between the ocular sensations of itch, pain, and dryness. Of note, it is not known whether itch is conveyed by dedicated pruriceptors or whether itch is encoded by nociceptive fibers (e.g. polymodal afferents) that express specific pruriceptors. After injury, ocular surface epithelial cells secrete a variety of inflammatory mediators (e.g. prostaglandin E2 (PGE2), serotonin, adenosine triphosphate (ATP) that activate peripheral nociceptors. Activated nociceptors secrete substance P (SP) which recruits inflammatory cells (T cells and macrophages) into the injured area. Inflammatory cells secrete various cytokines (tumor necrosis factor α (TNFα) and interleukin-1β (IL-1β), among others) which alter the ocular surface environment (e.g. increased osmolarity). These ocular surface alterations contribute to peripheral sensitization with increased responsiveness to external stimuli and spontaneous activation. Persistent peripheral traffic leads to amplified central nervous system processing (e.g. central sensitization) including augmented excitatory and decreased inhibitory transmission. These changes lead to a variety of unpleasant ocular surface sensations including itch, pain, and dryness, which are often co-morbid to each other.

NGF=nerve growth factor

Peripheral sensitization and chronic itch. In the skin, specialized mechanically insensitive (chemo-) nociceptor (CMi) fibers are responsible for the transmission of histaminergic itch and play a role in neuronal sensitization and inflammation. However, most chronic itch conditions do not respond to anti-histamines nor exhibit signs of CMi involvement. In fact, similar to chronic pain, chronic itch signaling is thought to occur via a non-histaminergic polymodal nociceptors mediated pathway. Unique nociceptors have been described in mediating chronic itch defined by the presence of specific G protein-coupled receptors (PAR2 and Mas-related G protein-coupled receptors (Mrgrp) A3+).

Relevance to dry eye. In order to understand the role of peripheral sensitization in DE, it is important to first review normal corneal anatomy and physiology. The cornea is innervated by the ophthalmic branch of the trigeminal nerve. Nerves enter the peripheral cornea in a radial fashion and lose their myelin sheath approximately 1 mm from the limbus. The nerves continue to branch and eventually turn 90 degrees towards the corneal epithelium. The terminal nerve endings interdigitate between the epithelial cells and reach past them so as to sense the ocular surface environment. Corneal nerves are primarily unmyelinated C fibers with myelinated Aδ fibers present to a lesser extent. The 3 most prevalent corneal nociceptors are the Aδ mechanoceptors (approximately 20%) which respond to indentations of the corneal surface, the polymodal nociceptors (approximately 70%) which

Trans Am Ophthalmol Soc / 115 / 2017

T5-8
individuals with Sjogren's syndrome and with a history of corneal surgery, including neuroma formation. In animal models, both nociceptive neurons in the central nervous system to their normal or subthreshold afferent input. Features of central sensitization have been found in individuals with chronic itch, pain, and DE.

Central sensitization and chronic pain. The neuronal changes leading to central sensitization are similar to those seen in peripheral sensitization, and include altered gene expression, signaling cascades (new synapses and rewiring of cortical circuits), inflammatory mediators, and altered ion channels. Both enhancement of excitatory neurons and blocking of inhibitory neurons occur on a central level leading to pain amplification and a perception of pain that is disproportional to the peripheral stimulus (e.g., hyperalgesia and allodynia). Within the brain, sensations of pain (and itch) are comprehensively processed by multiple regions involved in sensation and emotion (somatosensory cortex, amygdala, hippocampus, and hypothalamus).

Central sensitization and chronic itch. Central sensitization is also a component of chronic itch. In the spinal cord, MrgprA3+ neurons connect with gastrin-releasing peptide (GRP) receptor (GRPR) expressing neurons that are essential for itch transmission. In line with central sensitization, increased responses to PAR-2 agonists and up-regulation in GRP have been found in chronic itch. An imbalance of opioid receptors has also been described in chronic itch. Interestingly, activation of the µ opioid receptor decreases pain but increases itch while activation of the κ opioid receptor inhibits both itch and pain.

Relevance to dry eye. Clinical evidence of a role for central sensitization in DE comes from several lines of evidence. First, allodynia and hyperalgesia are frequent complaints in individuals with DE (for example, individuals report pain/sensitivity with wind and light) and there is often a disconnect between symptoms and signs of disease. Second, some individuals with DE symptoms report persistent pain after topical anesthesia, a treatment that quiets the firing of peripheral nociceptors. Finally, individuals with DE symptoms (as a group) have increased sensitivity to stimuli as tested by quantitative sensory testing (QST) on the forearm, signaling generalized hypersensitivity. Furthermore, specific QST metrics, such as the finding of increased temporal summation and persistent afferent sensations, further support central mechanisms underlying some portion of DE symptoms. Considering anatomy, peripheral nerves leave the cornea and first synapse in the Vi/Vc and Vc/C1 regions within the trigeminal nucleus caudalis. Similar to spinal dorsal horn neurons, second-order neurons in these regions receive both innocuous and noxious sensory information. Sensitization has been demonstrated in trigeminal nucleus caudalis neurons as demonstrated by increased sensitivity to ocular stimulus and increased convergent input from periorcular skin in models of lacrimal gland resection, uveitis and photokeratitiss. As in chronic non-ocular pain, decreased inhibition from higher brain centers likely also plays a role through inhibition of GABA receptor activity.

Supporting cells
Many cells (epithelial, glial) support peripheral and/or central nerves and are involved in both the maintenance of health and disease.

The role of supporting cells in chronic pain. In the peripheral nervous system, Schwann cells and epithelial cells interact with nerves. In the central nervous system, glial cells such as microglia, astrocytes, and oligodendrocytes modulate the function of neurons. For example, microglia have been found to rapidly activate in response to peripheral nerve injury, and subsequently produce a variety of pro-inflammatory mediators such as TNFα, IL1β, IL18, and PGE2. Astrocytes also become activated after nerve injury and subsequently lose their ability to maintain appropriate levels of potassium and glutamate (a powerful excitatory neurotransmitter) extracellularly, resulting in neuronal hyperexcitability. In fact, overstimulation of the N-methyl-D-aspartate (NMDA) glutamate receptor is an important component of central sensitization. Interestingly, sex related differences (chronic pain more frequent in females) have been observed in the pain phenotype which may be explained mechanistically. For example, one mechanism of central sensitization is the release of brain-derived neurotrophic factor (BDNF) which leads to alterations in potassium/chloride and a decreased strength of inhibitory transmission. In males, BDNF was released in response to microglia activation while in females, release required involvement of adaptive immune cells.

The role of supporting cells in chronic itch. Similar to pain, activation of glial cells plays an important role in chronic itch, with release of the cytokines TNF-α and IL-1β and BDNF. Again as in chronic pain, these mediators lead to enhanced excitatory transmission and decreased inhibition in spinal cord neurons.

Relevance to dry eye. Recent data suggest that the corneal epithelium plays a similar role to Schwann cells in interacting with corneal nerves, both in maintaining normal homeostasis and in responding to acute injury. For example, corneal epithelial cells have been found to phagocytize distal axon fragments within hours of corneal nerve crush wounds and are likely the source of some of the...
inflammatory mediators found in DE. Similar to chronic pain, there is a gender differential in DE with females having a higher frequency of disease.72

**TREATMENT**

Integrating the information presented above, the take home point is that many individuals with chronic DE symptoms (sensations of dryness, pain, or itch) have a neuropathic component, and as such treatments that target neuropathic pain can be considered as an adjuvant to ocular surface optimization in cases of recalcitrant and severe symptoms, in consultation with the appropriate specialists.

Treatments of chronic pain. There is no standardized algorithm for the treatment of patients with neuropathic pain; selected therapies depend on pain severity, underlying pathophysiology, and systemic co-morbidities. However, alpha 2 delta ligand antiepileptics (e.g. gabapentin; pregabalin) are often used as first line agents. Serotonin-norepinephrine reuptake inhibitors (e.g. duloxetine; venlafaxine) are often used as second line agents or as first line agents in patients with concomitant musculoskeletal pain or depression. Tricyclic anti-depressants (e.g. nortriptyline, amitriptyline) are usually not first line agents primarily due to their side effect profile. Based on response to treatment, combination therapies (antiepileptics and antidepressants) can be used in cases where monotherapy provides partial relief. Depending on the etiology of pain (e.g. post herpetic neuralgia), topical agents (lidocaine; capsaicin) can be used as first line therapies or as parts of a multimodal treatment plan. Short courses of corticosteroids or other antiglaucoma medications (topiramate, lamotrigine, carbamazepine, etc) are also used in specific circumstances. In addition, depending on pain severity, some opioids (e.g. tramadol) can be used in selected patients, in conjunction with the therapies above. However, the benefits of opioids should be weighed against their side effects, which among others may include addiction and hyperalgesia.73 Other measures, such as nerve stimulation or blocks, can be used as adjuvants or if there are specific indications, such as for neuropathic pain related to a specific nerve. In addition, delivering all these therapies in a multidisciplinary approach is important. Specificity, cognitive behavioral therapy focusing on coping mechanisms is vital when managing patients with chronic neuropathic pain.74

Treatments of chronic itch. Drug therapies that target neuropathic pain have also been effective in itch, such as gabapentinoids and anti-depressants. Anti-NGF therapies are being investigated as a treatment for both modalities as well. Based on the specific cytokines involved in chronic itch, anti-IL-4 IL-13, and IL-31 have also been tested in patients with atopic eczema.5 Kappa opioid agonists, such as butorphanol (which is a partial agonist of the κ-opioid receptor and has antagonist activity of the μ-opioid receptor), have also been found effective in reducing itch.75

Relevance to dry eye. DE treatments that target the ocular surface also have an effect on corneal nerves. For example, artificial tears and ointments protect the ocular surface and provide a barrier between nerves and the environment. Anti-inflammatory steroids (corticosteroids, cyclosporine, lifitigrast) and oral antibiotics (doxycycline) decrease ocular surface stress and inflammation with a beneficial effect on nerves. However, many patients have persistent symptoms on current therapies, especially those with NOP complaints.76 As such, other treatments need to be considered in those whose persistent symptoms are thought to be mediated in part by neuropathic mechanisms. For example, autologous serum tears may have a beneficial effect on corneal nerve structure and function, perhaps through the actions of NGF. In one retrospective study of 16 patients with corneal pain, improved photosensitivity and corneal nerve anatomy were noted with autologous serum tear use.59 In patients with centrally mediated pain, systemic therapies can be considered. We have anecdotally used gabapentin and pregabalin in such patients and have found beneficial effects in many patients at relatively high doses (gabapentin: 900-1200 mg 3 times daily; pregabalin 150 mg 2 times daily). A case report described the use of a trigeminal nerve stimulator and intrathecal catheter delivery of bupivacaine and fentanyl in a patient with ocular pain after refractive surgery as a proof of concept that strategies useful in non-ocular pain may be applied to ocular pain in appropriate individuals.77 More studies are needed to assess which anti-neuropathic therapies, in what combinations, will be most beneficial.

**STUDY LIMITATIONS**

Several study limitations must be considered when interpreting these results. First, the study sample consisted of United States veterans, the majority of whom are older males, and thus our results may not be generalized to other populations. However, it is encouraging that population of older male veterans had comparable levels of ocular pain complaints, systemic co-morbidities, and somatosensory dysfunction as a population of British women.56, 78, 79 Second, not all sub-types of DE were included in the study. Specific sub-types excluded were those with Sjogren’s syndrome, graft-versus-host disease, a history of corneal refractive surgery, glaucoma medication associated ocular surface disease, and contact lens were. As such, we can only comment on the relationship between ocular itch and DE symptoms in those without the above ocular conditions.

Third, limitations on our quantitation of ocular itch included using a 4 point scale and not capturing the temporal course of the itch (acute versus chronic). Fourth, all measurements were taken on one day and the retest reliability of our metrics is not known. Fifth, confocal microscopy was not available on the majority of individuals and therefore we cannot evaluate the relationship between nerve anatomy and ocular itch.

**STUDY CONCLUSIONS**

Despite these limitations, this study demonstrated that moderate-severe ocular itch associates with other ocular symptoms including sensations of dryness and NOP complaints. Mechanistically, patients with all 3 ocular sensations displayed evidence of chronic non-ocular pain and altered pain processing suggestive of central sensitization (e.g. hyperalgesia) and more severe mental health complaints (e.g. co-morbid depression and anxiety). This suggests that chronic eye symptoms, whether reported as dryness, itch, and/or pain, have shared underlying mechanisms that when severe may involve generalized neuronal dysfunction. This knowledge is
of importance to eye care professionals as identifying patients with a neuropathic component to their DE symptoms (whether pain, itch, or dryness) will allow for individualized treatment algorithms in which therapies that address sensitization can be added to those that target the ocular surface. More research is needed on which therapies, whether topical or systemic, that will be most effective in this patient population.

ACKNOWLEDGEMENTS

Funding/Support: The financial and material support of this paper comes from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S (Dr. Galor), NIH Center Core Grant P30EY014801, Research to Prevent Blindness Unrestricted Grant, NIH NIDCR RO1 DE022903 (Dr. Levitt), and the Department of Anesthesiology, Perioperative Medicine, and Pain Management, University of Miami Miller School of Medicine, Miami, FL.

Financial Disclosures: None

Contributions of Authors:

Design and conduct of the study; AG
Collection, management, analysis, and interpretation of the data: AG, WF
Preparation, review, or approval of the manuscript: AG, LS, WF, RL, KDS, GY

Other Acknowledgments: None

REFERENCES


